1. Pink Sheet
  2. >>Market Access

The Absurd Innovation Debate: Dueling Views Of HR 3 Miss The Point

 
• By Michael McCaughan

White House Council of Economic Advisors says US House drug price “negotiation” bill will reduce the number of innovative medicines by 100 over a decade; the Congressional Budget Office says more like 8-15. Both analyses miss the point – but also show that industry is losing a crucial piece of political ground.

Fencer woman with fencing sword. Fencers duel start concept. - Image

Get ready to hear lots of arguments about exactly how many new drugs the US will have to do without if it moves to an international reference price based “negotiation” model as proposed by the House of Representatives in HR 3.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access